NRTI — cytidine analog phosphorylated to FTC-TP, a chain-terminator for HIV-1 reverse transcriptase. Always combined with tenofovir as the dual NRTI backbone of HIV ART. Active against HBV. Excellent tolerability.
Half-Life & Elimination Curve (PO: 10h)
Plasma (PO)t½ Decay (10h)
0×t½0h100%(1.61 mg/L)
1×t½10h50%(0.803 mg/L)
2×t½20h25%(0.402 mg/L)
3×t½30h12.5%(0.201 mg/L)
4×t½40h6.3%(0.1 mg/L)
5×t½50h3.1%(50.2 µg/L)
Elimination t½10h (PO)
Rate Constant (ke)0.0693 h⁻¹
Time to Peak (Tmax)2.26h
Est. Peak (Cmax)1.61 mg/L
Clearance (CL)6.86 L/h
97% Washout (5×t½)50h
Dosing Guidelines
Oral (PO): Typical 200 mg
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 93% · Volume of Distribution (Vd): 99 L · Absorption (ka): 1.4 h⁻¹ (t½ka ≈ 30m) [PMID 27049055]